Quarterly report pursuant to Section 13 or 15(d)

Operating Segments (Tables)

Operating Segments (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Segment Reporting Information

The table below presents certain financial information of our operating segments for the three and nine months ended September 30, 2020 and 2019 (in thousands).

Segment Reporting for the Quarter Ended September 30, 2020

	Treatment			Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	7,066		$	23,106			—		$	30,172		$	—		$	30,172
Intercompany revenues		226			6			—			232			—			—
Gross profit		1,094			3,656			—			4,750			—			4,750
Research and development		49			7			81			137			20			157
Interest income		—			—			—			—			28			28
Interest expense		(34	)		(3	)		—			(37	)		(50	)		(87	)
Interest expense-financing fees		—			—			—			—			(58	)		(58	)
Depreciation and amortization		373			97			—			470			8			478
Segment income (loss) before income taxes		280			2,813			(81	)		3,012			(1,664	)		1,348
Income tax (benefit) expense		(170	)		2			—			(168	)		35			(133	)
Segment income (loss)		450			2,811			(81	)		3,180			(1,699	)		1,481
Expenditures for segment assets		95			24			—			119			3			122	⁽²⁾

Segment Reporting for the Quarter Ended September 30, 2019

	Treatment			Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	10,081		$	12,454			—		$	22,535		$	—		$	22,535
Intercompany revenues		75			38			—			113			—			—
Gross profit		3,338			1,819			—			5,157			—			5,157
Research and development		85			—			74			159			6			165
Interest income		—			—			—			—			77			77
Interest expense		(19	)		(5	)		—			(24	)		(75	)		(99	)
Interest expense-financing fees		—			—			—			—			(69	)		(69	)
Depreciation and amortization		243			79			—			322			6			328
Segment income (loss) before income taxes		2,244			1,193			(74	)		3,363			(1,413	)		1,950
Income tax expense		55			—			—			55			—			55
Segment income (loss)		2,189			1,193			(74	)		3,308			(1,413	)		1,895
Expenditures for segment assets		470			31			—			501			—			501	⁽³⁾

Segment Reporting for the Nine Months Ended September 30, 2020

	Treatment			Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	24,469		$	52,610			—		$	77,079		$	—		$	77,079
Intercompany revenues		879			19			—			898			—			—
Gross profit		5,533			7,167			—			12,700			—			12,700
Research and development		194			119			221			534			64			598
Interest income		1			—			—			1			111			112
Interest expense		(80	)		(13	)		—			(93	)		(213	)		(306	)
Interest expense-financing fees		—			—			—			—			(187	)		(187	)
Depreciation and amortization		912			259			—			1,171			18			1,189
Segment income (loss) before income taxes		2,577			5,162			(221	)		7,518			(4,597	)		2,921
Income tax (benefit) expense		(165	)		2			—			(163	)		35			(128	)
Segment income (loss)		2,742			5,160			(221	)		7,681			(4,632	)		3,049
Expenditures for segment assets		1,095			385			—			1,480			8			1,488	⁽²⁾

Segment Reporting for the Nine Months Ended September 30, 2019

	Treatment			Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	30,079		$	21,299			—		$	51,378		$	—		$	51,378
Intercompany revenues		83			101			—			184			—			—
Gross profit		8,921			2,008			—			10,929			—			10,929
Research and development		367			—			228			595			20			615
Interest income		—			—			—			—			265			265
Interest expense		(66	)		(18	)		—			(84	)		(209	)		(293	)
Interest expense-financing fees		—			—			—			—			(139	)		(139	)
Depreciation and amortization		713			236			—			949			19			968
Segment income (loss) before income taxes		5,731			318			(228	)		5,821			(4,003	)		1,818
Income tax expense		99			—			—			99			—			99
Segment income (loss)		5,632			318			(228	)		5,722			(4,003	)		1,719
Expenditures for segment assets		764			49			—			813			—			813	⁽³⁾

⁽¹⁾	Amounts reflect the activity for corporate headquarters not included in the segment information.

⁽²⁾	Net of financed amount of $751,000 and $883,000 for the three and nine months ended September 30, 2020, respectively.

⁽³⁾	Net of financed amount of $6,000 and $29,000 for the three and nine months ended September 30, 2019, respectively.